NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adverum Biotechnologies, Inc. ("Adverum" or "the Company") (NASDAQ:ADVM). Investors who purchased Adverum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADVM.

Investigation Details

On March 31, 2025, Adverum disclosed in an SEC filing that "certain of the Company's previously issued financial statements should no longer be relied upon due to non-cash errors identified in the accounting for tenant improvement allowances associated with an operating lease and sublease related to a building in North Carolina (the ‘NC Premises')." Following this news, Adverum announced it would restate its "financial statements as of and for the years ended December 31, 2022 and 2023, included in its Annual Report on Form 10-K for the year ended December 31, 2023 … as well as the unaudited condensed consolidated quarterly financial information for the quarterly periods in the years ended December 31, 2023 and 2024." Following this news, Adverum stock dropped over 12% on April 1, 2025.

What's Next?

If you are aware of any facts relating to this investigation or purchased Adverum securities, you can assist this investigation by visiting the firm's site: bgandg.com/ADVM. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire